|Company name||Jazz Pharmaceuticals PLC|
|Live stock price||[stckqut]JAZZ[/stckqut]|
|P/E compared to competitors||Good|
|Return on Assets growth||Good|
|Income / Rev growth||Good|
|Weighted ann. stock price increase||Poor|
|Confident Investor Rating||Fair|
|Target stock price (TWCA growth scenario)||$161.64|
|Target stock price (averages with growth)||$334.31|
|Target stock price (averages with no growth)||$444.8|
|Target stock price (manual assumptions)||$331.8|
The following company description is from Reuters: https://finance.yahoo.com/quote/jazz/profile?p=jazz
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in adult and pediatric patients with narcolepsy; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; and Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia. The company also offers JZP-258, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for some narcolepsy patients; JZP-385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP-458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and lurbinectedin, a product candidate under clinical investigation for the treatment of patients with relapsed small cell lung cancer. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma. The company was founded in 2003 and is headquartered in Dublin, Ireland.
Confident Investor comments: At this time, I think that a Confident Investor can cautiously invest in Jazz Pharmaceuticals PLC as long as the price is correct and the indicators that I describe in my book The Confident Investor are favorable. Most of the fundamentals of this company are good but there are some concerns.
If you would like to understand how to evaluate companies like I do on this site, please read my book, The Confident Investor. You can review the best companies that I have found (and I probably invest my own money in most of these companies) in my Watch List.
How was this analysis of Jazz Pharmaceuticals PLC calculated?
For owners of my book, “The Confident Investor” I offer the following analysis (you must be logged in to this site as a book owner in order to see the following analysis). If you have registered and cannot see the balance of this article, make sure you are logged in and refresh your browser.
In order to assist you in using the techniques of this book, the values that I used when calculating the Manual pricing above were:
- Stock price at the time of the calculation: $104.68
- Growth: 0.2
- Current EPS (TTM): $10.4273737370651
- P/E: 20.5948436392767
- Future EPS Calc: $25.94
- Future Stock Price Calc: $534.36
- Target stock price: $331.79
I hope that this makes you a Confident Investor.